Market revenue in 2021 | USD 111.1 million |
Market revenue in 2032 | USD 269.0 million |
Growth rate | 8.4% (CAGR from 2021 to 2032) |
Largest segment | Monoclonal antibodies |
Fastest growing segment | Thymectomy |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2032 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 64.36% in 2021. Horizon Databook has segmented the Germany myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
Germany is anticipated to be one of the most lucrative countries in Europe myasthenia gravis treatment market owing to the presence of a well-established healthcare system and high affordability of expensive MG drugs.
In addition, Germany’s supportive healthcare policies and initiatives such as expansion of telehealth to support the health of its citizens are expected to boost market growth in the country. Healthcare in Germany has successfully transitioned to a digital setup, beginning with Digital Healthcare Act (September 2019).
Germany motioned to reconstruct its national healthcare system, conditions that once demanded an in-person appointment to a physician’s clinic are now being managed online. The government allocates USD 228.27 million (EUR 200 million) per year for advancement of medical technology, which is expected to aid patients suffering from MG to improve their quality of life.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Germany myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account